Medicaid Rebate Suit Focuses On FDA Approval Status Of Acthar's New Indication
US government says Mallinckrodt avoided millions in Medicaid rebates by claiming Acthar’s added indication was approved as a new NDA rather than a supplemental application.
You may also be interested in...
Mallinckrodt Must Publicize Price Increases In Wake Of DOJ Settlement On Medicaid Rebates
Under corporate integrity agreement, Mallinckrodt must post proposed list price increases for Acthar and other non-generic products along with a link to executive compensation. $234m settlement resolves allegations it underpaid Medicaid rebates resulting from Acthar price hikes.
Acthar Gel Medicaid Rebates: Mallinckrodt Loses 'Gamble' Over FDA's NDA Numbering System
Mallinckrodt must pay $650m in retroactive Medicaid rebate payments; case shows how application filings can impact CMS reporting requirements and price-based reimbursements.
The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure
The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.